Biogen (BIIB) Tops Q2 EPS by 12c; Cuts FY15 Revenue Growth, EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bernstein Upgrades Biogen (BIIB) to Outperform
July 27, 2015 8:27 AM EDTBernstein upgraded Biogen (NASDAQ: BIIB) from Market Perform to Outperform with a price target of $385.00 (from $436.00).
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $300.03 yesterday.
... MoreBaird Downgrades Biogen (BIIB) to Neutral; Diminished Growth Prospects
July 27, 2015 6:35 AM EDTBaird downgraded Biogen (NASDAQ: BIIB) from Outperform to Neutral with a price target of $316.00 (from $480.00), saying lackluster sales and lowered guidance leaves a growth void.
Analyst Brian Skorney commented, "We're aware that this downgrade may be too little, too late given... More
Biogen's (BIIB) Decline Seen as 'Overreaction' at Deutsche Bank
July 24, 2015 3:36 PM EDTDeutsche Bank maintained a Buy rating on Biogen (NASDAQ: BIIB) with a price target of $460. Shares declined after Biogen reported Q2 results and cut full-year guidance. In the view of analyst Robyn Karnauskas, the decline was an "overreaction," though she agrees with sentiment.
"The disappointing run of BIIB continued in Q215 as the co substantially revised 2015 FY guidance due to weaker outlook for Tecfidera.... More
Stocks Hit Session Lows; Biotech, Homebuilders Lead Slump
July 24, 2015 1:33 PM EDTStocks hit session lows Friday afternoon, with the S&P down 0.75% and the Nasdaq lower by 0.5% -- despite huge gains in Amazon.com (NASDAQ: AMZN).
Biotech was among the worst performing sectors with ETFs like iShares Nasdaq Biotechnology (NASDAQ:... More
Biogen (BIIB) Trading at 'Pharma-Like' Multiple, Cowen Says
July 24, 2015 1:04 PM EDTCowen analyst Eric Schmidt reiterated his Outperform rating and $494 price target on Biogen (NASDAQ: BIIB), with shares down nearly 20% on disappointing Q2 results and outlook. Schmidt maintained his bullish view, saying the stock is trading at a 'pharma-like' multiple.
Schmidt commented,... More
Biogen (BIIB) Worth a 'Hard Look' when Smoke Clears, Stifel Says
July 24, 2015 12:19 PM EDTStifel analyst Thomas Shrader weighed in on Biogen (NASDAQ: BIIB) following disappointing Q2 results, which has shares down 18.4% intra-day. While retaining his Hold rating, the analyst said the stock is worth a hard look when the smoke clears.
Shrader commented, "Biogens numbers were... More
